儿童复发或难治性白血病CAR-T治疗的长期生存与价值
该成本效果分析模型将tisagenlecleucel(一种嵌合抗原受体T细胞疗法)的试验证据外推至患者终生,估计其长期生存与价值。结论认为tisagenlecleucel可能带来生存获益,且定价似乎与这些获益相符。
核心结论
- Tisagenlecleucel可能提供生存获益,且其定价似乎与这些获益相符。
- 研究提示支付方和创新者应开发新型支付模式,以降低长期价值相关的风险和不确定性,并提供保障以确保高价值医疗。
研究设计与样本
- 成本效果分析,采用决策分析模型将试验证据外推至患者终生时限。
- 目标人群为小于25岁的复发或难治性或第二次及以后复发的B细胞急性淋巴细胞白血病患者,使用灵活参数模型直接外推无事件生存和总生存曲线。
- 敏感性分析和情景分析评估证据和模型假设的不确定性,数据分析时间为2017年12月1日至2018年3月31日。
关键数值与推荐
- 复发或难治性B细胞急性淋巴细胞白血病儿童和年轻成人的5年无病生存率为10%至20%。
临床怎么用
- 支付方和创新者可考虑开发新型支付模式,以降低长期价值的不确定性并保障高价值医疗。
局限性
- 模型基于试验证据外推,长期生存数据来自 flexible parametric modeling 和数字化Kaplan-Meier曲线插补。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Among children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia, the rate of 5-year disease-free survival is 10% to 20%. Approval of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, represents a new and potentially curative treatment option. However, tisagenlecleucel is expensive, with a current list price of $475 000 per one-time administration. OBJECTIVE: To estimate the long-term survival and value of tisagenlecleucel for children and young adults with B-cell acute lymphoblastic leukemia. DESIGN, SETTING, AND PARTICIPANTS: In this cost-effectiveness analysis, a decision analytic model was designed to extrapolate trial evidence to a patient lifetime horizon. The survival evidence for the model was extracted from 3 studies: B2202 (enrolled patients from April 8, 2015, to November 23, 2016), B2205J (enrolled patients from August 14, 2014, to February 1, 2016), and B2101J (enrolled patients from March 15, 2012, to November 30, 2015). Long-term survival and outcomes of patients younger than 25 years with B-cell acute lymphoblastic leukemia that is refractory or in second or later relapse were derived using flexible parametric modeling from the direct extrapolation of event-free survival and overall survival curves. The published Kaplan-Meier curves were digitized from November 1, 2017, to November 30, 2017, using an algorithm to impute patient-level time-to-event data. Sensitivity and scenario analyses assessed uncertainty in the evidence and model assumptions to further bound the range of cost-effectiveness. Data were analyzed from December 1, 2017, to March 31, 2018. INTERVENTIONS: The primary intervention of interest was tisagenlecleucel. The comparator of interest was the chemoimmunotherapeutic agent clofarabine. MAIN OUTCOMES AND MEASURES: Model outcomes included life-years gained, quality-adjusted life-years (QALYs) gained, and incremental costs per life-year and QALY gained. RESULTS: Forty percent of patients initiating treatment with tisagenlecleucel are expected to be long-term survivors, or alive and responding to treatment after 5 years. Tisagenlecleucel had a total discounted cost of $667 000, with discounted life-years gained of 10.34 years and 9.28 QALYs gained. The clofarabine comparator had a total discounted cost of approximately $337 000, with discounted life-years gained of 2.43 years and 2.10 QALYs gained. This difference resulted in an incremental cost-effectiveness ratio of approximately $42 000 per life-year gained and approximately $46 000 per QALY gained for tisagenlecleucel vs clofarabine. These results were robust to probabilistic sensitivity analyses. Across scenario analyses that included more conservative assumptions regarding long-term relapse and survival, the incremental cost-effectiveness ratio ranged from $37 000 to $78 000 per QALY gained. CONCLUSIONS AND RELEVANCE: Tisagenlecleucel likely provides gains in survival and seems to be priced in alignment with these benefits. This study suggests that payers and innovators should develop novel payment models that reduce the risk and uncertainty around long-term value and provide safeguards to ensure high-value care.
引用
- Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia. JAMA Pediatr. 2018. PMID: 30304407. doi:10.1001/jamapediatrics.2018.2530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。